Not yet recruitingNot applicableNCT07096037

Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

Studying Osgood-Schlatter disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Faculty of Medicine, Sousse
Principal Investigator: Amira Zairi
Department of Biochemistry, Faculty of Medicine of Sousse, University of Sousse, Tunisia
Intervention: Urtica dioica cataplasm(other)
Enrollment: 90 enrolled
Eligibility: 7-15 years · MALE
Timeline: 2025 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07096037 on ClinicalTrials.gov

Other trials for Osgood-Schlatter disease

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT07446517
Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes
Medical University of Gdansk

See all trials for Osgood-Schlatter disease →

← Back to all trials